GUWAHATI: Dr. Randeep Guleria of All India Institute of Medical Sciences (AIIMS), Delhi said to expect a vaccine for children by September.
Guleria is the leading pulmonologist and a crucial member of the government’s task force on Covid-19. He told that Covaxin’s data for children after completion of the Phase 2/3 trials will be available by September and the approval is expected by the same month.
He also added,“If Pfizer-BioNTech’s vaccine gets a green signal in India then that could also be an option for children.”
Screening of children for these clinical trials has already been commenced by Delhi AIIMS. COVAXIN’s Phase 2/3 trials would be conducted on 525 volunteers at several sites. The process started on June 7 that includes children between the age of 2 to 18 years.
Bharat Biotech, which developed this vaccine, had last month obtained permission from the Drugs Controller General of India (DCGI) to carry out its trials on children.
Until lately, it was being broadly assumed that a new wave of COVID-19 infections would have an effect on children harder. Although, there is no data available yet to prove that theory, said the experts.
Quoting a recent seroprevalence study by AIIMS and the WHO, the Indian government has made it clear that the level of antibodies has been found quite similar among both adults and children.